SS
CPRX

SBI Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

SBI Securities’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Sell
480
-276
-37% -$8.15K ﹤0.01% 1650
2026
Q1 		$18.7K Buy
756
+27
+4% +$643 ﹤0.01% 1484
2025
Q4 		$17K Buy
729
+309
+74% +$6.88K ﹤0.01% 1508
2025
Q3 		$8.27K Buy
420
+11
+3% +$226 ﹤0.01% 1852
2025
Q2 		$8.88K Sell
409
-124
-23% -$2.93K ﹤0.01% 1753
2025
Q1 		$12.9K Buy
533
+155
+41% +$3.49K ﹤0.01% 1497
2024
Q4 		$7.89K Buy
+378
New +$8.12K ﹤0.01% 1744

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities's CPRX Position: Q2 2026 in Review

SBI Securities reduced its Catalyst Pharmaceutical (CPRX) stake by 37% in Q2 2026, selling an estimated $8.15K and leaving 480 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1650.

SBI Securities first reported a position in CPRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $18.7K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • SBI Securities held 480 shares of Catalyst Pharmaceutical worth $15.1K as of Q2 2026.
  • SBI Securities sold 276 Catalyst Pharmaceutical shares in Q2 2026, an estimated $8.15K.
  • Catalyst Pharmaceutical made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1650 holding.
  • SBI Securities first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Catalyst Pharmaceutical position peaked at $18.7K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.